Press Releases
Mar. 20, 2017 biOasis Announces Non-Brokered Private Placement
VANCOUVER, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) announces a nonbrokered private placement of up to 4,500,000 units at a price of $0.70 per unit of gross proceeds of up to $3,150,000 (the “Offering”). Each unit will consist of one common share and one-half common share purchase warrant. Each whole warrant entitles… Read more »
Jan. 23, 2017 biOasis Provides AGM Update – Expanding The biOasis Deal Flow Pipeline
VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (BBB), has provided a corporate update in advance of its Annual and Special Meeting of Shareholders to be held at 1780 – 400 Burrard Street, Vancouver, BC, on January 23, 2017… Read more »
Dec. 22, 2016 biOasis Announces Adoption of Restricted Share Unit Plan
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) announces that subject to approval by the TSX Venture Exchange (“TSXV”) and ratification by the Company’s shareholders at the 2016 Annual and Special General Meeting of shareholders (the “AGM”), the Company adopted a restricted share unit plan (the “RSU Plan”). Further details regarding the RSU… Read more »
Nov. 6, 2016 biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research’s December Journal
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it’s team is attending BIO Europe, November 7th to 9th, in Cologne, Germany. In addition, the company announced that Dr. Paul Lockman’s recently published paper on biOasis’s… Read more »
Oct. 23, 2016 biOasis Engages Rising Tide Equity to Increase Global Awareness
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it has engaged Rising Tide Equity to increase its global awareness. Investors are increasingly using digital media and non-traditional media outlets to identify potential investment opportunities. Recent… Read more »
Sep. 20, 2016 biOasis Enters Into a License Agreement With Vaccinex Inc
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis”), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced it has entered into a License Agreement (the “Agreement”) with Vaccinex Inc. (“Vaccinex”). Under the terms of the Agreement, Vaccinex will have the right to commercialize its… Read more »
Aug. 29, 2016 biOasis Announces Publication of Scientific Paper – Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced the publication of a peer-reviewed scientific paper detailing the results of an in-vivo study of the treatment of Metastatic HER2+ Breast Cancer brain tumors in an animal… Read more »
Jul. 10, 2016 biOasis Announces the Issuance of an Additional US Patent for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent covering a refined subset of fragments found within Melanotransferrin or P97 for the delivery of therapeutic agents to the brain. The U.S.… Read more »
May. 17, 2016 biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016
biOasis to showcase their Transcend technology for the transport of drugs across the blood-brain barrier (BBB)
Apr. 21, 2016 biOasis Technologies Enters into a License Agreement with Astellas Research Institute of America LLC
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC (“Astellas”). The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the… Read more »